Valuation: Hikma Pharmaceuticals PLC

Market Cap 448.64Cr 402.34Cr 370.8Cr 336.75Cr 637.32Cr 42TCr 655.11Cr 4.44TCr 1.77TCr 23TCr 1.68TCr 1.65TCr 71TCr P/E 2026 *
11.6x
P/E 2027 * 10.6x
Enterprise Value 599.2Cr 537.36Cr 495.23Cr 449.76Cr 851.2Cr 56TCr 874.96Cr 5.93TCr 2.36TCr 30TCr 2.25TCr 2.2TCr 95TCr EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.63x
Free-Float
63.7%
Yield 2026 *
4.03%
Yield 2027 * 4.21%
1 week-6.77%
Current month-6.12%
1 month+0.81%
3 months-1.46%
6 months+14.64%
Current year+4.84%
1 week 1,611
Extreme 1611
1,750
1 month 1,569
Extreme 1569
1,762
Current year 1,187
Extreme 1187
1,762
1 year 1,187
Extreme 1187
1,762
3 years 1,187
Extreme 1187
2,360
5 years 1,174.5
Extreme 1174.5
2,387
10 years 814.2
Extreme 814.2
2,768
Manager TitleAgeSince
Chief Executive Officer 69 01/12/2025
Director of Finance/CFO - 26/02/2026
Chief Tech/Sci/R&D Officer 64 26/02/2026
Director TitleAgeSince
Director/Board Member 69 14/10/2005
Director/Board Member 54 15/12/2025
Chairman 69 15/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/06/26 Sell

Investor Relations Manager

-26,558 0.0124%
01/06/26 Exercice

Director

72,763 0.0339%
01/06/26 Exercice

Director

20,650 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.77%+4.50%-7.28% 448.64Cr
+1.44%+1.63%+48.17%+139.63% 1,27600Cr
-0.47%+5.49%+49.03%+90.68% 68TCr
+0.20%+2.76%+34.37%+112.06% 52TCr
+0.17%+2.76%+44.07%+69.71% 39TCr
-0.48%+2.34%+70.66%+46.02% 36TCr
+0.76%+2.27%+31.59%+60.36% 31TCr
-1.29%+0.90%+5.77%+37.60% 29TCr
0.00%+0.86%+43.74%+74.04% 25TCr
+0.92%+2.03%+44.62%+125.07% 21TCr
Average -0.03%+1.43%+37.65%+74.79% 43TCr
Weighted average by Cap. -0.09%+2.50%+43.67%+97.03%

Financials

2026 *2027 *
Net sales 345.23Cr 309.61Cr 285.33Cr 259.13Cr 490.42Cr 32TCr 504.11Cr 3.42TCr 1.36TCr 17TCr 1.3TCr 1.27TCr 55TCr 357.12Cr 320.27Cr 295.16Cr 268.05Cr 507.31Cr 33TCr 521.47Cr 3.53TCr 1.41TCr 18TCr 1.34TCr 1.31TCr 57TCr
Net income 42Cr 37Cr 34Cr 31Cr 59Cr 3.89TCr 61Cr 411.06Cr 163.78Cr 2.09TCr 155.89Cr 152.58Cr 6.6TCr 45Cr 40Cr 37Cr 34Cr 64Cr 4.19TCr 65Cr 442.54Cr 176.32Cr 2.25TCr 167.83Cr 164.27Cr 7.1TCr
Net Debt 150.56Cr 135.02Cr 124.44Cr 113.01Cr 213.88Cr 14TCr 219.85Cr 1.49TCr 593.62Cr 7.56TCr 565.03Cr 553.05Cr 24TCr 132.02Cr 118.4Cr 109.12Cr 99Cr 187.55Cr 12TCr 192.78Cr 1.31TCr 520.54Cr 6.63TCr 495.47Cr 484.96Cr 21TCr
Projected Income Statement - Annual - Hikma Pharmaceuticals PLC
Logo Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.
Employees
9,500
Date Price Change Volume
10/26/10 GBX 1,625.00 0.00% 6,64,194
09/26/09 GBX 1,625.00 -1.52% 15,25,837
06/26/06 GBX 1,650.00 -2.77% 8,17,940
05/26/05 GBX 1,697.00 -3.69% 8,22,670
04/26/04 GBX 1,762.00 +1.09% 7,36,955
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Hikma Pharmaceuticals PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
21.65USD
Average target price
26.61USD
Spread / Average Target
+22.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Hikma Pharmaceuticals PLC